Last 12 months
Inside the activity.
1 purchase rows · 3 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2017 Filed Apr 4, 2017 20:07 UTC |
Hatfield Jeffrey S.Director
|
GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-17-024676 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2027-04-03 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning May 3, 2017, such that this option will be fully exercisable on April 3, 2020, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:24 UTC |
Matsuoka GroveSee Remarks
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009079 · doc4.xml · derivative · entry 1 Matsuoka Grove · CIK 0001673494 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:09 UTC |
King David JohnSee Remarks
|
GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009057 · doc4.xml · derivative · entry 1 King David John · CIK 0001684902 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:03 UTC |
Amanullah AshrafVice President, Manufacturing
|
GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009043 · doc4.xml · derivative · entry 2 Amanullah Ashraf · CIK 0001670631 · Vice President, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units (RSUs) are scheduled to vest in three equal annual installments beginning on February 7, 2018, such that the RSUs will fully vest on February 7, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The restricted stock units (RSUs) are scheduled to vest in three equal annual installments beginning on February 7, 2018, such that the RSUs will fully vest on February 7, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:03 UTC |
Amanullah AshrafVice President, Manufacturing
|
GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009043 · doc4.xml · derivative · entry 1 Amanullah Ashraf · CIK 0001670631 · Vice President, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:36 UTC |
Shukla SanjayChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009100 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:27 UTC |
MENDLEIN JOHNDirector · CEO and Director
|
GrantEmployee Stock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009086 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 21:31 UTC |
Ravindran Sanuj K.Chief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009093 · doc4.xml · derivative · entry 1 Ravindran Sanuj K. · CIK 0001662549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 21:06 UTC |
Blake John TSenior Vice President, Finance
|
GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009051 · doc4.xml · derivative · entry 2 Blake John T · CIK 0001657162 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units (RSUs) are scheduled to vest in three equal annual installments beginning on February 7, 2018, such that this grant will be fully vest on February 7, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The restricted stock units (RSUs) are scheduled to vest in three equal annual installments beginning on February 7, 2018, such that this grant will be fully vest on February 7, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 21:06 UTC |
Blake John TSenior Vice President, Finance
|
GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009051 · doc4.xml · derivative · entry 1 Blake John T · CIK 0001657162 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 16:53 UTC |
SCHIMMEL PAULDirector
|
PurchaseCommon Stock | 10,000 | $2.28 | $22,818.00 |
DisclosureSEC source: 0001209191-16-156424 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 721,814 F1 · ownership.nature: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/20. Read SEC document |
| December 20, 2016 Filed Dec 21, 2016 18:37 UTC |
Amanullah AshrafVice President, Manufacturing
|
PurchaseCommon Stock | 11,000 | $2.25 | $24,748.90 |
DisclosureSEC source: 0001209191-16-156372 · doc4.xml · nonDerivative · entry 1 Amanullah Ashraf · CIK 0001670631 · Vice President, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 16:53 UTC |
SCHIMMEL PAULDirector
|
PurchaseCommon Stock | 15,000 | $2.27 | $34,110.00 |
DisclosureSEC source: 0001209191-16-156424 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 711,814 F1 · ownership.nature: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/20. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 11:54 UTC |
MENDLEIN JOHNDirector · CEO and Director
|
PurchaseCommon Stock | 69,000 | $2.20 | $151,662.00 |
DisclosureSEC source: 0001209191-16-156269 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,971 F1 · price: Represents the weighted average price for the shares. The shares were purchased at prices ranging from $2.125 to $2.25 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan ("ESPP") on May 15, 2016 and 2,500 shares acquired under the ESPP on November 15, 2016. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 00:41 UTC |
SCHIMMEL PAULDirector
|
PurchaseCommon Stock | 10,000 | $2.40 | $23,973.00 |
DisclosureSEC source: 0001209191-16-156022 · doc4.xml · nonDerivative · entry 4 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 696,814 F1 · ownership.nature: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| December 15, 2016 Filed Dec 20, 2016 00:41 UTC |
SCHIMMEL PAULDirector
|
PurchaseCommon Stock | 40,000 | $2.50 | $99,912.00 |
DisclosureSEC source: 0001209191-16-156022 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 686,814 F2 · price: Represents weighted price for the shares. The shares were purchased at prices ranging from $2.3469 to $2.6411 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| September 23, 2016 Filed Dec 20, 2016 00:41 UTC |
SCHIMMEL PAULDirector
|
GiftCommon Stock | 12,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156022 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 646,814 F1 · ownership.nature: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| September 23, 2016 Filed Dec 20, 2016 00:41 UTC |
SCHIMMEL PAULDirector
|
GiftCommon Stock | 12,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156022 · doc4.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,440 Read SEC document |
| September 21, 2016 Filed Sep 22, 2016 16:53 UTC |
King David JohnSee Remarks
|
GrantEmployee Stock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001209191-16-142490 · doc4.xml · derivative · entry 1 King David John · CIK 0001684902 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2026-09-21 F1 · derivative.exercise_date: 1/4 of the shares subject to this option shall vest and become exercisable on September 21, 2017, and the remainder shall thereafter vest in 36 equal monthly installments, such that this option is fully exercisable on September 21, 2020. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 18:47 UTC |
Matsuoka GroveSee Remarks
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141652 · doc4.xml · derivative · entry 1 Matsuoka Grove · CIK 0001673494 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 18:57 UTC |
Amanullah AshrafVice President, Manufacturing
|
GrantEmployee Stock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141655 · doc4.xml · derivative · entry 1 Amanullah Ashraf · CIK 0001670631 · Vice President, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 18:53 UTC |
Shukla SanjayChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 27,500 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141654 · doc4.xml · derivative · entry 1 Shukla Sanjay · CIK 0001671026 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 23:26 UTC |
Cubitt AndrewVP, Product Protection
|
GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141679 · doc4.xml · derivative · entry 1 Cubitt Andrew · CIK 0001641212 · VP, Product Protection 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 22:59 UTC |
Ravindran Sanuj K.Chief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 45,500 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141657 · doc4.xml · derivative · entry 1 Ravindran Sanuj K. · CIK 0001662549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 22:37 UTC |
Blake John TVice President, Finance
|
GrantEmployee Stock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141649 · doc4.xml · derivative · entry 1 Blake John T · CIK 0001657162 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.